F. Vera-Badillo

发表

Value of Biomarker Expression for Randomized Clinical Trial Design: One (More) Missed Opportunity.

D. Berman, F. Vera-Badillo, A. Robinson, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER3 overexpression and survival in solid tumors: a meta-analysis.

A. Pandiella, F. Vera-Badillo, A. Ocaña, 2013, Journal of the National Cancer Institute.

Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer.

I. Tannock, F. Vera-Badillo, R. Shapiro, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).

I. Tannock, A. Evans, Lisa I. Wang, 2019, The oncologist.

Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio

I. Tannock, F. Vera-Badillo, J. D. de Bono, 2014, Cancer.

Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.

I. Tannock, F. Vera-Badillo, A. Ocaña, 2018, Cancer treatment reviews.

Adjuvant Radiation Therapy After Radical Nephrectomy in Patients with Localized Renal Cell Carcinoma: A Systematic Review and Meta-analysis.

I. Tannock, F. Vera-Badillo, A. Ocaña, 2019, European urology oncology.

Impact of Geographic Region on Benefit of Approved Anticancer Drugs Evaluated in International Phase III Clinical Trials.

F. Vera-Badillo, A. Ocaña, E. Amir, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Peri-operative allogeneic blood transfusion and outcomes after radical cystectomy: a population-based study

F. Vera-Badillo, C. Booth, D. Siemens, 2017, World Journal of Urology.

Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population

W. Mackillop, F. Vera-Badillo, C. Booth, 2017, Clinical genitourinary cancer.

Influence of censoring on conclusions of trials for women with metastatic breast cancer.

I. Tannock, G. Pond, F. Vera-Badillo, 2015, European journal of cancer.

Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.

I. Tannock, J. Knox, E. Atenafu, 2014, European journal of cancer.

Evolution in the eligibility criteria of randomized controlled trials for systemic cancer therapies.

F. Vera-Badillo, A. Ocaña, E. Amir, 2016, Cancer treatment reviews.

Management of Favorable-risk Advanced Renal Cell Carcinoma: Is Dual Therapy the Answer?

F. Vera-Badillo, G. Procopio, A. Kartolo, 2021, European urology open science.

A Systematic Review and Meta-Analysis of Dual Therapy in Patients with Advanced Renal Cell Carcinoma of Favourable Risk.

F. Vera-Badillo, I. Durán, A. Robinson, 2021, Urology.

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer.

I. Tannock, J. Bono, J. Knox, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Retreatment of men with metastatic castrate‐resistant prostate cancer with abiraterone

I. Tannock, J. Knox, F. Vera-Badillo, 2014, The Prostate.

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

I. Tannock, G. Pond, M. Moore, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Fulvestrant for advanced breast cancer: a meta-analysis.

F. Vera-Badillo, A. Ocaña, E. Amir, 2013, Cancer treatment reviews.

Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression

A. Pandiella, F. Vera-Badillo, A. Ocaña, 2016, PloS one.

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.

I. Tannock, G. Sonpavde, B. Tombal, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials.

I. Tannock, G. Sonpavde, B. Tombal, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: A systematic review and meta-analysis.

M. Brundage, F. Vera-Badillo, C. Booth, 2018, Critical reviews in oncology/hematology.

Canadian consensus on TRK‐inhibitor therapy for NTRK fusion‐positive sarcoma

S. Banerji, F. Vera-Badillo, R. Deyell, 2021, International journal of cancer.

Clinical stage I synchronous bilateral testicular germ cell tumor with different histopathology: a case report

F. Vera-Badillo, R. Garza-Guajardo, C. Salazar-Mejía, 2020, The Pan African medical journal.

Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?

F. Vera-Badillo, W. Kassouf, A. Kartolo, 2021, European urology.

Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma

T. Powles, G. Sonpavde, C. Sternberg, 2022, European Journal of Cancer.

M. Stockler, W. Parulekar, M. Frydenberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Duration of suppression of bone turnover following treatment with zoledronic acid in men with metastatic castration-resistant prostate cancer

I. Tannock, Z. Nugent, F. Vera-Badillo, 2017, Future science OA.

Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP.

F. Vera-Badillo, J. Izard, A. Robinson, 2021, European urology.

Spin and bias: the tip of the iceberg.

I. Tannock, F. Vera-Badillo, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

M. Stockler, W. Parulekar, M. Frydenberg, 2019, The New England journal of medicine.

Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.

Ben Tran, Arnoud J Templeton, Ian F Tannock, 2014, Journal of the National Cancer Institute.

Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis

A. Pandiella, F. Vera-Badillo, A. Ocaña, 2014, PloS one.

Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

I. Tannock, T. Hermanns, F. Vera-Badillo, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Prognostic role of Ki-67 score in localized prostate cancer: A systematic review and meta-analysis.

A. Berlin, F. Vera-Badillo, Galileo A Gonzalez-Conchas, 2017, Urologic oncology.

PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis.

F. Vera-Badillo, C. Booth, E. Amir, 2019, Cancer treatment reviews.

Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis.

I. Tannock, B. Escudier, J. Knox, 2015, European urology.

Chromophobe renal cell carcinoma: A review of an uncommon entity

F. Vera-Badillo, I. Durán, E. Conde, 2012, International journal of urology : official journal of the Japanese Urological Association.

Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients

F. Vera-Badillo, S. Sigurdson, F. Y. de Moraes, 2020, Frontiers in Oncology.

Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?

B. Gyawali, F. Vera-Badillo, S. Van Wambeke, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience.

I. Tannock, J. Knox, E. Atenafu, 2014 .

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.

M. Stockler, W. Parulekar, M. Frydenberg, 2021, European urology.

Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses

A. Pandiella, F. Vera-Badillo, A. Ocaña, 2015, Oncotarget.

Relevance of randomised controlled trials in oncology.

I. Tannock, F. Vera-Badillo, C. Booth, 2016, The Lancet. Oncology.

Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis.

I. Tannock, F. Vera-Badillo, A. Ocaña, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III Trials of Targeted Anticancer Therapies: Redesigning the Concept

I. Tannock, F. Vera-Badillo, A. Ocaña, 2013, Clinical Cancer Research.

Prognostic relevance of receptor tyrosine kinase expression in breast cancer: a meta-analysis.

A. Pandiella, J. Jordán, F. Vera-Badillo, 2014, Cancer treatment reviews.

Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs.

Philippe Bédard, F. Vera-Badillo, A. Barnadas, 2015, Journal of Clinical Oncology.

Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review.

Y. Yamada, M. Bilsky, F. Moraes, 2020, JAMA oncology.

Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma.

G. Bjarnason, F. Vera-Badillo, A. Parmar, 2019, Clinical genitourinary cancer.

Management of small HER2 overexpressing tumours

Philippe Bédard, F. Vera-Badillo, A. Ocaña, 2012, Breast Cancer Research and Treatment.

Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

I. Tannock, P. Bedard, F. Vera-Badillo, 2014, Journal of the National Cancer Institute.

Fibroblast Growth Factor Receptor 3 Mutation as a Prognostic Indicator in Patients with Urothelial Carcinoma: A Systematic Review and Meta-analysis

D. Berman, F. Vera-Badillo, C. Booth, 2020, European urology open science.

Volume of systemic cancer therapy delivery and outcomes of patients with solid tumors: A systematic review and methodologic evaluation of the literature

M. Raphael, F. Vera-Badillo, C. Booth, 2020 .

Immunotherapy in prostate cancer: review of the current evidence

F. Vera-Badillo, I. Durán, B. Pérez-Valderrama, 2015, Clinical and Translational Oncology.

Circulating DNA and Survival in Solid Tumors

A. Pandiella, F. Vera-Badillo, G. Serrano-Heras, 2015, Cancer Epidemiology, Biomarkers & Prevention.

CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.

M. Stockler, J. Dancey, M. Tsao, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

HER3 Overexpression and Survival in Solid Tumors

A. Pandiella, F. Vera-Badillo, A. Ocaña, 2012 .

Benefit and Harms of New Anti-Cancer Drugs

F. Vera-Badillo, E. Amir, A. Templeton, 2013, Current Oncology Reports.

From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC).

I. Tannock, M. Moore, J. Knox, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer

F. Vera-Badillo, A. Ocaña, E. Amir, 2015, PloS one.

Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer

I. Tannock, Philippe Bédard, F. Vera-Badillo, 2015, Journal of Clinical Pathology.

Honorary and ghost authorship in reports of randomised clinical trials in oncology.

Arnoud J Templeton, Ian F Tannock, An-Wen Chan, 2016, European journal of cancer.

Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial.

Sally Hopewell, Douglas G Altman, Isabelle Boutron, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.

I. Tannock, J. Knox, F. Vera-Badillo, 2014 .

Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis

I. Tannock, F. Vera-Badillo, A. Ocaña, 2014, Breast Cancer Research and Treatment.

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.

M. Stockler, W. Parulekar, M. Frydenberg, 2023, The Lancet. Oncology.

The Impact of Special Access Programs (SAP) on Prescribing Patterns in Metastatic Castration Resistant Prostate Cancer (mCRPC)

I. Tannock, J. Knox, F. Vera-Badillo, 2021 .

Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis

F. Vera-Badillo, S. Sigurdson, S. Malone, 2022, Current oncology.

Bias in reporting of randomised clinical trials in oncology.

I. Tannock, A. Chan, S. Alibhai, 2016, European journal of cancer.